US Pharma MarketingNovartis and Orionis strike second molecular glue deal for $40M upfront
Novartis inks second molecular glue deal with Orionis Biosciences, paying $40M upfront and up to $1.4B in milestones across multiple disease areas. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
Novartis is doubling down on its partnership with Orionis Biosciences in a deal worth $40 million upfront and up to $1.4 billion spread across milestones.
The Boston and Belgian biotech will ...
Source: Endpoints News